Bringing the Oncology Community Together

Dr. Julie Gralow Discusses the SWOG S0500 Trial

Julie R. Gralow, MD
Published Online: Friday, December 13, 2013


Julie R. Gralow, MD, director, Breast Medical Oncology, Seattle Cancer Care Alliance, clinical research division, member, Fred Hutchinson Cancer Care Center, professor, Medical Oncology Division, University of Washington School of Medicine, discusses the SWOG S0500 trial, which evaluated different treatments in patients with metastatic breast cancer who had elevated circulating tumor cell (CTC) levels.

Gralow says the CTC levels of newly diagnosed metastatic breast cancer patients were measured before receiving chemotherapy. If the levels were low, the patients were put in an observation arm. If the levels were high, the patients received one cycle of chemotherapy before having their CTC levels tested again.

Gralow says if the patient’s CTC levels were low, they continued with chemotherapy treatment but if the patient’s CTC levels remained the same or were elevated, those patients were randomized to either keep going on the same therapy or to change them to a different type of chemotherapy. Additionally, Gralow notes, bevacizumab and trastuzumab were allowed in the trial.

Gralow says the results showed that the patients who had low CTC levels to begin with did the best. The patients who had elevated levels prior to chemotherapy but had lower levels after chemotherapy did moderately well while the patients whose levels remained elevated throughout the trial did poorly no matter what.

The conclusion, Gralow says, is that it is a poor prognostic sign to have high CTC levels. The trial also showed that switching to a different chemotherapy sooner does not improve outcomes. For these patients, a clinical trial to look at new targeted therapies should be considered, since chemotherapy is not effective in this population of patients.

<<< View more from the 2013 SABCS Meeting

Related Articles
AR Findings Highlight Detailed Tumor-Profiling Study
A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression
Phase III Clinical Trials in HER2-Positive Breast Cancer
Expert panelists explore several large clinical trials examining therapies for patients with HER2-positive breast cancer that are currently ongoing or have recently completed.
Experts Support Broader Pertuzumab Use in HER2-Positive Breast Cancer
The recent approval of pertuzumab as part of a combination neoadjuvant treatment for patients with early-stage breast cancer has paved the way for wider use of the regimen in preoperative settings.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.